Lorem Ipsum
Lorem Ipsum
Treatment for sickle cell disease (now 1% of children in East Africa and a growing clinical burden) including trials of hydroxyurea and prophylactic antimalarials; This work includes a fellowship on immunological reactions to multiple transfusions in children with sickle cell disease
Collaborations
Internal:
External:
Funding: